Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Secondary Prevention Treatment in Patients Who Have Suffered a Cardiovascular Event

This study has been completed.
Information provided by (Responsible Party):
AstraZeneca Identifier:
First received: June 14, 2011
Last updated: August 29, 2011
Last verified: August 2011

AstraZeneca was interested in knowing how Cardiologists and Physicians treat patients who have suffered a cardiovascular event.

Cardiovascular Events

Study Type: Observational
Study Design: Time Perspective: Retrospective
Official Title: Secondary Prevention Treatment in Patients Who Have Suffered a Cardiovascular Event.

Further study details as provided by AstraZeneca:

Enrollment: 88
Study Start Date: January 2010
Study Completion Date: July 2010
Primary Completion Date: July 2010 (Final data collection date for primary outcome measure)

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Patients with cardiovascular events


Inclusion Criteria:

  • All patients who has experienced cardiovascular events

Exclusion Criteria:

  • Patients with no cardiovascular events.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

No publications provided

Responsible Party: AstraZeneca Identifier: NCT01395550     History of Changes
Other Study ID Numbers: NIS-CZA-XXX-2011/1
Study First Received: June 14, 2011
Last Updated: August 29, 2011
Health Authority: South Africa: None processed this record on February 27, 2015